Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-150
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
BCR-ABL1
Downstream target
MYC
Cancer name
Chronic Myeloid Leukemia
Cancer site
Leukemia
Treatment type
Chemotherapy
Drug
Imatinib
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Tissue resource
bone marrow samples from the chronic myeloid leukemia patients and peripheral blood mononuclear cells samples from healthy volunteers
BCR-ABL1-positive chronic myeloid leukemia cell lines K562
BCR-ABL1-positive chronic myeloid leukemia cell lines MEG-01
BCR-ABL1-positive chronic myeloid leukemia cell lines KCL-22
BCR-ABL1-negative acute myeloid leukemia cell lines HL-60
BCR-ABL1-negative acute myeloid leukemiaL cell lines KG-1
Experiment
qRT-PCR
Institute
Institute of Hematology and Blood Transfusion
Leibniz Institute-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH/DSMZ
Country
Czech Republic
Germany
Continent
Europe
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.